Nathan Collins discusses how the SynFini automated chemistry platform is accelerating drug development and discovery. Learn more about SynFini at: https://www.sri.com/case-studies/synfini.
Nathan Collins is the Chief Strategy Officer of SRI Biosciences in Menlo Park, CA. In part one of this episode of The Dish TV they discuss the processes and problems of new drug discovery today, and how the SynFini platform is exponentially accelerating the rate at which new, targeted drugs can be created.
SRI’s The Dish TV highlights the most special part of SRI—our people. Join Host Reenita Hora, Head of Marketing and Communications, for casual conversations with guests from across our institute about what brought them to and keeps them at SRI, as well as the latest world-changing innovations to come out of their divisions. At SRI, we’re inventing a better future together.